New Talent Is In At Sanofi, Biogen
This article was originally published in The Pink Sheet Daily
Sanofi appointed immunology expert Yong-Jun Liu as head of research, leaving a vacancy at Medimmune, while Biogen recruited its new chief commercial officer Michel Vounatsos from Merck.
You may also be interested in...
Elias Zerhouni says Sanofi's ongoing R&D revamp has produced improved innovative results with controlled spending, in part by emphasizing cutting-edge product development ahead of research.
Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.
Pfizer expects Comirnaty and Paxlovid revenues to be drastically lower this year after pushing 2022 revenues over $100bn. Management said 2023 would be a transition year for the company.